10-Year Financial / Non-Financial Data

(For the fiscal years as of / ended March 31)

	JGAAP				
	2009	2010	2011	2012	
Revenue	980,803	883,086	847,105	848,548	
Selling, general and administrative (SG&A) expenses	418,558	347,125	349,306	348,287	
Percentage of revenue (%)	42.7%	39.3%	41.2%	41.0%	
Percentage of revenue excluding R&D expenditures (%)	35.5%	32.3%	33.3%	33.8%	
Operating profit	42,722	61,160	38,379	35,518	
Percentage of revenue (%)	4.4%	6.9%	4.5%	4.2%	
Profit (loss) before tax	(20,383)	90,703	19,938	(9,495)	
Net income (loss) (JGAAP) /				, , , , , , , , , , , , , , , , , , ,	
Profit (loss) attributable to owners of parent (IFRS)	(50,561)	52,527	3,866	(48,985)	
Percentage of revenue (%)	_	5.9%	0.5%	_	
EBITDA margin*1 (%)	12.8%	13.3%	9.9%	9.5%	
EBITDA margin (Medical Business)*2 (%)	27.0%	29.2%	26.9%	26.6%	
R&D expenditures	70,010	61,850	67,286	61,356	
Percentage of revenue (%)	7.1%	7.0%	7.9%	7.2%	
Capital expenditures	55,632	34,323	32,699	37,961	
Depreciation and amortization	44,594	43,099	34,188	33,787	
Amortization of goodwill	37,881	12,918	11,619	11,103	
Financial indicators	0.,00.	.2,0.0	,	,	
Total assets*3	1,038,253	1,104,528	1,019,160	966,526	
Total net assets (JGAAP)*3 / Total equity (IFRS)	110,907	163,131	115,579	48,028	
Equity ratio (JGAAP) / Ratio of equity attributable	110,007	100,101	110,070	10,020	
to owners of parent to total assets (IFRS) (%)	10.0%	14.1%	11.0%	4.6%	
Interest-bearing debt	642,839	661,481	648,787	642,426	
Net debt	505,763	454,698	435,226	442,338	
Inventories	95,540	89,959	92,929	102,493	
	1.2	1.3	1.3	1.4	
Inventory turnover period (months)	132,720	203,013	210,385	198,661	
Cash flowe from operating activities	36,864	76,245	30,469	30,889	
Cash flows from operating activities	(15,964)	(20,967)	19,003	(35,735)	
Cash flows from investing activities	(3,751)	17,355	(37,359)	(5,761)	
Cash flows from financing activities	(30.2%)	40.6%	2.9%	(62.3%)	
Return on equity (ROE) (%)	4.1%	4.9%	0.4%		
Return on assets (ROA) (%)	4.170	4.9%	0.4%	(4.9%)	
Net income (loss) per share (JGAAP) / Basic earnings per share (IFRS) (yen)	(188.85)	194.90	14.39	(183.54)	
Total equity per share (JGAAP) / Equity attributable	(100.00)			(100101)	
to owners of parent per share (IFRS) (yen)	387.31	576.63	421.37	167.76	
Price earnings ratio (PER)*4 (times)	_	15.4	160.8	_	
Price book-value ratio (PBR) (times)	4.1	5.2	5.5	8.1	
Outstanding market value (billions of yen)	428.6	813.8	627.7	367.3	
Cash dividends per share (yen)	20	30	30	_	
Average exchange rate					
U.S. dollar / Yen	100.54	92.85	85.72	79.08	
Euro / Yen	143.48	131.15	113.12	108.98	
	140.40	101.10	110.12	100.00	
Non-financial indicators	36,503	35,376	34,391	34,112	
Number of employees*5					
(Average number of temporary employees)	(—)	(—)	(5,336) 62,4%	(5,009) 62.1%	
Overseas employees as a percentage of employees (%)	62.1%	63.3%	62.4%	62.1%	
Percentage of women in management roles*6 (%)	0.8%	0.9%	0.9%	0.8%	
Percentage of employees with disabilities*7 (%)	1.7%	1.8%	1.8%	1.9%	

^{*1} At the Company, EBITDA is calculated using the following assumptions: EBITDA = Operating profit + Depreciation and amortization that is included in cost of sales or SG&A expenses + Amortization of goodwill that is included in SG&A expenses.

EBITDA margin = EBITDA / Revenue

*2 At the Company, EBITDA (Medical Business) is calculated using the following assumptions: EBITDA = Segment profit in the Medical Business + Depreciation and amortization that is included in cost of

sales or SG&A expenses + Amortization of goodwill that is included in SG&A expenses. EBITDA margin (Medical Business) = EBITDA (Medical Business) / Revenue
*3 In line with the issuance of IAS No. 19 "Employee Benefits" (revised on June 16, 2011) to be applied for fiscal years beginning on or after January 1, 2013, certain overseas subsidiaries adopted IAS No. 19 effective from the fiscal year ended March 31, 2014, and changed their method of recognizing actuarial gain or loss. This change has been applied retroactively to the figures for the fiscal year ended March 31, 2013.

(Millions of yen)

					IFRS	
2013	2014	2015	2016	2017	2017	2018
743,851	713,286	764,671	804,578	748,050	740,557	786,497
343,121	367,011	398,889	430,773	414,855	397,697	426,596
46.1%	51.5%	52.2%	53.5%	55.5%	53.7%	54.2%
37.6%	42.1%	42.5%	43.4%	44.9%	43.0%	42.9%
35,077	73,445	90,962	104,464	76,487	71,192	81,029
4.7%	10.3%	11.9%	13.0%	10.2%	9.6%	10.3%
19,142	16,425	8,934	70,800	81,686	62,481	76,665
8,020	13,627	(8,737)	62,594	78,191	42,783	57,064
1.1%	1.9%	_	7.8%	10.5%	5.8%	7.3%
10.6%	16.8%	18.5%	19.2%	17.4%	16.9%	17.0%
29.0%	29.7%	29.1%	29.5%	27.4%	27.4%	26.5%
63,379	66,796	74,101	81,415	79,178	79,178	89,469
8.5%	9.4%	9.7%	10.1%	10.6%	10.7%	11.4%
28,109	37,810	47,743	64,445	49,347	60,683	65,255
33,899	36,850	41,219	39,912	44,658	54,290	52,913
9,683	9,457	9,421	9,867	8,642		
960,239	1,027,475	1,081,551	1,000,614	991,062	960,032	978,663
151,907	331,284	357,254	384,283	430,880	396,228	444,259
45 50/	00.40/	00.00/	00.00/	40.00/	44 40/	45.00/
15.5%	32.1%	32.9%	38.2%	43.3%	41.1%	45.2%
560,390	415,831	354,421	321,138	286,357	285,970	247,974
330,780	163,710	144,546	154,584	86,926	86,505	56,735
99,307	98,595	107,387	111,558	124,064	125,319	139,309
1.6	1.7	1.6	1.6	1.9	2.0	2.1
225,782	251,344	209,809	166,323	199,431	199,465	191,239
25,233	72,388	66,811	48,621	90,194	102,052	95,146
33,455	(20,273)	(39,612)	(52,897)	(8,305)	(20,814)	(53,312)
(42,436)	(39,693)	(70,185)	(33,870)	(44,244)	(43,615)	(51,058)
8.3%	5.7%	(2.6%)	17.0%	19.3%	11.3%	13.6%
0.8%	1.4%	(0.8%)	6.0%	7.9%	4.4%	5.9%
28.96	41.05	(25.53)	182.90	228.47	125.01	166.84
493.30	962.83	1,038.64	1,117.24	1,252.96	1,153.45	1,297.01
76.4	80.2		23.9	18.7	34.2	24.2
4.5	3.4	4.3	3.9	3.4	3.7	3.1
675.8	1,127.4	1,530.0	1,499.2	1,466.6	1,466.6	1,384.5
_		10	17	28	28	28
83.10	100.24	109.93	120.14	108.38	108.38	110.85
107.14	134.37	138.77	132.58	118.79	118.79	129.70
20 607	20 700	21 540	20 206	24 607	24 697	25.022
30,697	30,702	31,540	33,336	34,687	34,687	35,933
(2,240)	(2,978)	(1,374)	(1,257)	(1,298)	(1,298)	(1,511)
62.4%	62.5%	63.2%	63.3%	63.7%	63.7%	63.7%
0.9%	1.0%	1.2%	1.4%	1.9%	1.9%	2.3% 2.2%

^{*4} Price earnings ratio (PER) for the fiscal years ended March 31, 2012 and 2015 are omitted as Olympus recorded net loss for these fiscal years.

*5 The average number of temporary employees is stated in parentheses from the fiscal year ended March 31, 2011, as the number of temporary employees is over 10% of the total number of employees.

*6 Figures for percentage of women in management roles only include individuals in Japan.

*7 Figures for percentage of employees with disabilities are as of June 1 of the respective year and only include individuals in Japan.